Carpe Diem,

See Page 24 of most recent MD&A on SEDAR (my bolding added):

"In May 2018, we obtained a US$30 million senior secured term loan from Third Eye Capital Corporation, as agent for a syndicate of lenders. The loan bears interest at a rate of 10% per annum, payable monthly, and has a maturity date of May 4, 2019. The loan is secured by all of our assets and contains certain restrictive financial covenants, covenants relating to the completion of the BETonMACE clinical trial (top line data on or before January 31, 2019) and other customary covenants. Pursuant to the loan agreement with Third Eye the Company must maintain a cash balance greater than $5 million, a current ratio greater than 1:1 (excluding warrant liability, unearned licensing rights fee and debt from current liabilities), and a market capitalization greater than CAD$150 million, as well as other customary covenants. The Third Eye Loan is subject to mandatory prepayment provisions requiring at least 50% of the net cash proceeds of asset dispositions, licensing, distribution or partnership agreements, royalties, debt or equity issuances, grants and tax refunds to be applied to repayment of the Third Eye Loan."